Contrast-enhanced CT based radiomics for prediction of 3-year disease progression in NSCLC patients after anti-PD-1-targeted therapy.

Authors

Wen Huang, Min-Jia Lin, Yi-Ting He, Hong Zhou, Yi Chen, Min Zong

Published in

European journal of radiology open. Volume 17. Pages 100775. Epub Jun 18, 2026.

Abstract

This study aimed to develop and validate a radiomics-based model derived from contrast-enhanced computed tomography (CE-CT) to predict 3-year disease progression in patients with non-small-cell lung cancer (NSCLC) receiving anti-PD1 immunotherapy.
A total of 173 patients with NSCLC undergoing anti-PD1 immunotherapy were retrospectively enrolled. We developed a integrated model based on Radscore by selecting radiomics features from target lesions (TL) and clinical features derived from pretreatment CE-CT images. The receiver operating characteristic (ROC) curve was used to evaluate the predictive performance of different models. Model interpretability was enhanced via Shapley Additive Explanations (SHAP).
Chronic obstructive pulmonary disease (COPD) and tumor stage were identified as significant clinical predictors of 3-year disease progression. The radiomics model achieved area under the curve (AUC) values of 0.758 (95% CI: 0.663-0.852) and 0.815 (95% CI: 0.618-1.000) in training and testing cohorts, respectively. The integrated model showed improved performance, with AUCs of 0.802 (95% CI: 0.721-0.884) and 0.836 (95% CI: 0.663-1.000), respectively. The nomogram exhibited superior net clinical benefit compared to radiomics- or clinical-only models. SHAP analysis identified shape Sphericity, gldm Small Dependence High Gray Level Emphasis, glszm Gray Level Variance, glszm Small Area High Gray Level Emphasis as key imaging features associated with 3-year disease progression.
We developed an integrated clinical-radiomics model that effectively identifies NSCLC patients most likely to benefit from anti-PD-1 therapy. Using SHAP-based explainability, we clarified the contribution of imaging features, enabling more personalized treatment strategies.

PMID:
42376198
Bibliographic data and abstract were imported from PubMed on 30 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.